MRC Medical Bioinformatics Centre
Medical Bioinformatics Centre
The MRC Medical Bioinformatics Centre (MBC) aims to create and sustain the infrastructure, facilities, understanding and culture changes to enable ground-breaking and productive bioinformatics research at the interface between the clinic, health records and high volume molecular and phenotypic data sets.
It is part of the MRC’s £90m commitment to support informatics research, infrastructure and scientists, with the aim of building a sustainable capability in health and biomedical informatics in the UK.
The Centre’s work has focused on six areas, developing new insights into the factors that drive disease and providing indicators that inform treatment, to enable better, more personalised and more effective medicine and healthcare:
- Cancer genomics and malignant melanoma
- Genotype, phenotype and response to radiotherapy in rectal cancer
- Inherited rare diseases
- Proteomic biomarkers
- Patient similarity searches in lymphoma treatment
- Enhancing the value of the MRC-funded rheumatoid arthritis stratified medicine and RA-MAP consortia through linkage to complex data sets
The Centre has generated high impact academic outputs, including 340 linked publications and has leveraged 14.4 million additional funding. The Centre is collaborating with a wide range of partners including business organisations (e.g IBM, TPP Ltd), health care providers at a national level (e.g The Farr Institute, Cancer Research UK) and locally (e.g Leeds NIHR, Leeds Teaching Hospitals Trust).
Big Data and Health Research
A fighting chance of survival: life-saving stents for heart attacks
A study of 300,000 heart attack patients, led by the University of Leeds, has found rapid rates in the uptake of a treatment which improves a patient’s chances of survival after a major heart attack.More
Improving treatment of Rheumatoid Arthritis
Using information collected by general practitioners (GPs) in their practices (primary care) to improve the information on comorbidities available within our RA research cohorts.More